Polidori Andrea, Malagoli Mattia, Giacalone Rosario, Brichetto Giampaolo, Monti Bragadin Margherita, Prada Valeria
Scientific Research Area, Fondazione Italiana Sclerosi Multipla (FISM), 16149 Genova, Italy.
Servizio Riabilitazione Liguria, Associazione Italiana Sclerosi Multipla (AISM), 16149 Genova, Italy.
Life (Basel). 2024 May 30;14(6):703. doi: 10.3390/life14060703.
Multiple Sclerosis (MS) is a demyelinating and chronic disease with variable neurological symptoms. There are different scales that score the level of disability, but only few papers have taken into consideration the 5-times sit-to-stand (5STS) test and the 30 s chair stand test (30CST), which are valid and easily obtainable indicators of other neurological diseases. The aim of our research is to verify the validity, reproducibility, and responsiveness of these tests. Patients afflicted with MS were enrolled in the AISM outpatient facility. The inclusion criterion was an EDSS score less than 6.5. We performed the 5STS, 30CST, and timed 25-foot walk (T25-FW) tests and recorded EDSS scores in the first evaluation. Then, we recorded the performance after 5 days (conducted by a second blind operator to ensure test-retest reproducibility), and the last evaluation was made after 12 sessions of physiotherapy. We recruited 38 patients diagnosed with MS. The results show significant data regarding validity, reproducibility, and responsiveness for both scales. The data argue in favor of adding these tests to the relevant clinical assessments. These two tests are simple, reliable, and easy to administer, and the data confirm that they can be included in the evaluation of patients with MS.
多发性硬化症(MS)是一种具有多种神经症状的脱髓鞘慢性疾病。有不同的量表对残疾程度进行评分,但只有少数论文考虑了5次坐立试验(5STS)和30秒椅子站立试验(30CST),这两项试验是其他神经疾病有效且易于获取的指标。我们研究的目的是验证这些试验的有效性、可重复性和反应性。患有MS的患者在意大利多发性硬化症协会(AISM)门诊机构登记入组。纳入标准是扩展残疾状态量表(EDSS)评分低于6.5。我们进行了5STS、30CST和25英尺定时步行试验(T25-FW),并在首次评估时记录EDSS评分。然后,我们在5天后(由第二位盲法操作人员进行以确保重测可重复性)记录表现,最后一次评估在12次物理治疗后进行。我们招募了38名被诊断为MS的患者。结果显示了关于这两个量表的有效性、可重复性和反应性的显著数据。这些数据支持将这些试验添加到相关临床评估中。这两项试验简单、可靠且易于实施,数据证实它们可纳入MS患者的评估中。